Drug Insights

Expert Tips for Searching Ketamine on Synapse

9 February 2024
2 min read

Ketamine is a small molecule drug that acts as a modulator at the N-methyl-D-aspartate (NMDA) receptor. It is marketed under the trade name KETALAR and is primarily used as an anesthetic drug. Ketamine was first approved for medical use in the United States in 1970 by Endo International. This drug is available as a slightly acidic, sterile solution for intravenous or intramuscular injection. Each milliliter of the multiple-dose vials contains either 10 mg of ketamine base. Ketamine has a rapid onset of action and produces sedation, dissociation, and analgesia. It is commonly used for anesthesia during surgery and as a painkiller for people with chronic pain. Ketamine may have some potential as an antidepressant, but more research is needed to determine its efficacy and safety for this indication. The use of ketamine as an anesthetic or painkiller may cause some side effects, including hallucinations, nausea, and vomiting. Click on the image below to begin the exploration journey of Ketamine through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Sirius Therapeutics Launches Phase One Study for Innovative Anticoagulant to Combat Thromboembolic Conditions
Latest Hotspot
3 min read
Sirius Therapeutics Launches Phase One Study for Innovative Anticoagulant to Combat Thromboembolic Conditions
9 February 2024
Sirius Therapeutics has initiated a first-stage clinical study for an advanced, extended-duration Factor XI siRNA anticoagulant, aimed at addressing thromboembolic conditions.
Read →
Navigating Health Information: How to Use Synapse to Search for Mirtazapine
Drug Insights
2 min read
Navigating Health Information: How to Use Synapse to Search for Mirtazapine
9 February 2024
Mirtazapine acts as an alpha-2 adrenergic receptor (ADRA2) antagonist, causing the release of norepinephrine and serotonin in the brain.
Read →
Takeda and Protagonist Sign Global Deal for Experimental Blood Disorder Drug, Rusfertide
Latest Hotspot
3 min read
Takeda and Protagonist Sign Global Deal for Experimental Blood Disorder Drug, Rusfertide
9 February 2024
Takeda Pharmaceuticals and Protagonist Therapeutics have signed a global licensing and partnership deal for the advanced experimental blood disorder medication, Rusfertide.
Read →
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Alprazolam
Drug Insights
2 min read
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Alprazolam
9 February 2024
Alprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.